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Non–small cell lung carcinoma (NSCLC) is the most common cause of cancer deaths, with platin-based
combination chemotherapy the most efficacious therapies. Gains in overall survival are modest, highlighting the
need for novel therapeutic approaches including the development of next-generation platin combination regimens.
The goal of this study was to identify novel regulators of platin-induced cytotoxicity as potential therapeutic targets
to further enhance platin cytotoxicity. Employing RNA-seq transcriptome analysis comparing two parental NSCLC
cell lines Calu6 and H23 to their cisplatin-resistant sublines, Calu6cisR1 and H23cisR1, activating transcription
factor 3 (ATF3) was robustly induced in cisplatin-treated parental sensitive cell lines but not their resistant sublines,
and in three of six tumors evaluated, but not in their corresponding normal adjacent lung tissue (0/6). Cisplatin-
induced JNK activation was a key regulator of this ATF3 induction. Interestingly, in both resistant sublines, this JNK
induction was abrogated, and the expression of an activated JNK construct in these cells enhanced both cisplatin-
induced cytotoxicity and ATF3 induction. An FDA-approved drug compound screen was employed to identify
enhancers of cisplatin cytotoxicity that were dependent on ATF3 gene expression. Vorinostat, a histone
deacetylase inhibitor, was identified in this screen and demonstrated synergistic cytotoxicity with cisplatin in both
the parental Calu6 and H23 cell lines and importantly in their resistant sublines as well that was dependent on
ATF3 expression. Thus, we have identified ATF3 as an important regulator of cisplatin cytotoxicity and that ATF3
inducers in combination with platins are a potential novel therapeutic approach for NSCLC.
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Lung cancer, predominantly non–small cell lung cancer (NSCLC), is
the most common cause of cancer death, surpassing the next five most
common causes combined [1]. Platins, particularly cisplatin and
carboplatin, are the most active agents in NSCLC [2], and
platin-based chemotherapy combinations are typically the first-line
therapy in the advanced (metastatic) setting [3]. However, the overall
gains in survival have been modest, with a median survival of
approximately 12 months in patients receiving platin doublet
chemotherapy compared to 4 months in untreated patients [4].
Approximately 30% of patients will show antitumor responses, but
these responses are not durable, with treatments resulting in a
relatively modest effect on overall patient survival [5]. Identification
of novel therapeutic approaches including next-generation platin
combination strategies is urgently required.
Although platin-induced cytotoxicity results from DNA damage
that drives their cytotoxicity, the mechanisms and cellular pathways
underlying the proapoptotic effect of these chemotherapeutic agents
are largely undefined [6]. Understanding the mechanisms regulating
tumor cell cytotoxicity may uncover novel therapeutic strategies to
enhance the efficacy of these platin-based chemotherapeutics.
Cisplatin and carboplatin are primarily considered to be
DNA-damaging anticancer drugs forming different types of adducts
in reaction with cellular DNA [2]. The final cellular outcome of DNA
adduct formation is generally apoptotic cell death, and multifactorial
cellular mechanisms of resistance to platin-based chemotherapeutics
include apoptosis inhibition [6]. DNA is the recognized primary
target of cisplatin and carboplatin activity [7], but gaps still remain in
our understanding of the process that translates cisplatin-induced
DNA damage into its therapeutically beneficial process of apoptosis.
Two significant cellular pathways have been demonstrated to play key
roles in platin-induced apoptosis/cytotoxicity: the mitogen-activated
protein kinase cascades (MAPKinase) and the tumor suppressor
p53 [8,9].
There is significant interest in the role of MAPKinase pathways in
platin's mode of action. The major MAPK subfamily members
include the extracellular signal–regulated kinases (ERK), the c-Jun
N-terminal kinases (JNK), and the p38 kinases [10,11]. A number of
studies have demonstrated that all three kinase members can be
activated following exposure of tumor cells to cisplatin and play a role
in regulating cisplatin-induced apoptosis [12,13]. However, the
downstream targets of these pathways have not been well
characterized. Employing RNA-seq transcriptome analysis, we
identified a known MAPKinase-induced cellular stress pathway,
highlighted by activating transcription factor 3 (ATF3) [14,15],
which was specifically induced by cisplatin in sensitive but not
resistant cells and was a key regulator of cisplatin-induced cytotoxicity
and resistance. Elevated and sustained levels of stress-induced ATF3
enhance apoptosis, suggesting that ATF3 inducers may enhance the
cytotoxic activity of platins, representing a potentially novel and
rational therapeutic approach.
Materials and Methods
Tissue Culture
The human NSCLC tumor–derived cell lines Calu6 and
NCI-H23 (H23), the breast cancer cell lines MCF7 and T47D,
and the prostate cancer cell lines LNCAP and PC3 were obtained
from the ATCC (Rockville, MD, USA). The murine embryonicfibroblasts (MEFs) ATF3−/− deficient in ATF3 expression through
gene knockout and their wild-type counterparts were kindly provided
by Dr. T. Hai, (Ohio State University, Columbus, OH). Cells were
maintained in Dulbecco’s modified Eagle’s medium (Media Services,
Ottawa Regional Cancer Centre) supplemented with 10% fetal
bovine serum (Medicorp, Montreal, QC, Canada). To derive
cisplatin-resistant Calu6 and H23 sublines (designated cisR), cells
were plated and treated with 2 μg/ml cisplatin until a surviving
fraction of about 10−6 remained [16]. Following this cisplatin
treatment regimen, sublines isolated from single cells were propagat-
ed. Cisplatin, carboplatin, doxorubicin, and docetaxel were provided
by the pharmacy at the Ottawa Hospital Cancer Centre, Ottawa. For
JNK expression experiments, Calu6cisR1 cells plated at 3 × 105 in
6-well plates were transfected with 2 μg of a JNK1a1-expressing
plasmid (Addgene, Plasmid #13,798) [17] using FuGENE HD
Transfection Reagent (Roche, Mississauga, ON) as per manufac-
turer's protocol. Following 24 hours, medium was removed and
replaced with medium containing cisplatin for an additional 48
hours. The JNK inhibitor II (SP600125) and vorinostat were
purchased from Calbiochem, Gibbstown, NJ.
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium bromide
(MTT) Assay
In 96-well flat-bottom plates (Costar, Corning, NY), 5000 cells/
150 μl of cell suspension were used to seed each well. Cells were
incubated overnight to allow for cell attachment and recovery and
assayed for MTT activity following drug treatments. For analysis, 50
μl of a 5-mg/ml solution of the MTT tetrazolium substrate (Sigma) in
phosphate-buffered saline was added and incubated for up to 6 hours
at 37°C. The resulting violet formazan precipitate was solubilized by
the addition of 100 μl of 0.01 M HCl in 10% SDS (Sigma-Aldrich,
St. Louis, MO) solution shaking overnight at 37°C. The plates
were then analyzed on a microplate reader (Synergy Mx
Monochromator-Based Multi-Mode Microplate Reader) using
Gen5 software, both from Biotek Instruments (Winooski, VT), at
570 nm to determine the optical density of the samples.
Transcriptome Analysis (RNA Sequencing)
Total RNA was isolated employing the RNeasy Isolation Kit
(Qiagen, Frederick, MD). Messenger RNA expression profiling was
performed using NuGen reagents (www.nugeninc.com). After
amplification, libraries compatible with Illumina NGS methods
were prepared using the Ovation Ultra Low Library Prep Kit
(NuGen). The quality of each library was assessed using a Bioanalyzer
2100 (Agilent Technologies). Kappa Library Quant Kits (KappaBio-
systems; www.kapabiosystems.com) were used for library quantita-
tion. Cluster generation and 2 × 36 bp paired-end sequencing was
performed over a single lane using the Illumina GAIIx or HiSeq
Genome Analyzer workstation. The RNA-Seq data were analyzed and
quantified employing Cufflinks [18].
Western Blot Analysis
Cells plated at 0.7 × 106/60-mm dish were incubated
overnight and treated with the indicated drug for 24 hours. Protein
samples were collected in RIPA buffer (50 mM Tris-CL pH 7.5,
150 mM sodium chloride, 1 mM EDTA, 1% Triton-X-100,
0.25% sodium deoxycholate, 0.1% SDS) containing the protease
inhibitors 50 mM sodium fluoride, 1 mM sodium orthovanadate,
10 mM β-glycerolphosphate, and 1× Protease Inhibitor Cocktail
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Protein Assay (Mississauga, Ontario, Canada) and a Biomate 3
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA). The
Western blot methodology employed was previously described [19].
Antibodies specific for ATF3 were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA); Actin from Sigma; and ERK,
phospho-ERK (Tyr204), Jun, phospho-Jun (Ser73), Hsp27, and
phospho-hsp27 (Ser78) from Cell Signaling Technology (Beverly,
MA). Visualization of protein bands was performed using the
Supersignal West Pico Chemiluminescent Substrate (Pierce, Rock-
ford, IL) and developed using the Syngene Bio-Imaging System
(Syngene, Frederick, MD).
Quantitative Reverse Transcriptase Polymerase Chain Reaction
(Q-RT-PCR)
Cells plated at 0.8 × 106 cells per 10-cm dish were incubated at 37°C
overnight and then treated with cisplatin for 24 hours. Total RNA was
extracted from cell samples using the RNAeasy kit (Qiagen). RNA
concentrations were quantified using a NanoDrop ND-1000 spectro-
photometer (Wilmington, DE). One microgram of total RNA was
reverse-transcribed to complementary DNA for Q-RT-PCR as
previously described [20]. The Applied Biosystems AB 7500
Real-Time PCR system (Applied Biosystems, Foster City, CA) was
used to detect amplification. A real-time PCR was carried out
employing Taq Man Gene Expression Assay Primer/Probe (Applied
Biosystems, ATF3, HS00231069) and the housekeeping gene human
GAPDH (20×) (Applied Biosystems, HS4333764-F) as per manufac-
turer’s instructions. Three independent experiments were performed to
determine the average gene expression and standard deviation.
Patient tumor tissue and matched adjacent normal lung tissue from
at least 10 cm from the tumor were collected upon resection
(lobectomy) and similarly evaluated (Ottawa Hospital Research
Ethics Board; Protocol # 20120559-01H). Areas containing tumor
were identified by routine gross pathological examinations. Cores of
approximately 2 mm were obtained using a sterile biopsy punch that
were further sliced with a scalpel to obtain approximately 2 × 2 × 1 mm
tumor slices. The slices were randomized, and three slices were placed
into each well of a 24-well plate and cultured in Dulbecco’s modified
Eagle’s medium (HyClone) supplemented with 10% heat-inactivated
FBS (Medicorp) and 100 U/ml antibiotic/antimycotic solution
(Sigma). After 48-hour drug treatments, the tumor slices were processed
for RNA extraction and RT-PCR analysis of ATF3 mRNA levels as
described above in triplicate.
High-Throughput Chemical Library Screen
Wild-type and ATF3−/− MEFs cells were treated with a chemical
library of 1200 FDA-approved compounds (Prestwick Chemical,
Illkirch, France) [21]. All compounds were supplied in a 10-mM
stock diluted inDMSO and were used at a final concentration of 5 μM.
Cytotoxicity was evaluated for the drug library for each cell line
employing the MTT assay; a greater than 20% difference in response
in the wild type versus the ATF3−/−MEFs was considered a “hit.” A
second screen was then performed in Calu6 cells pretreated with the
drug library at 1 μM for 24 hours and then for an additional 48 hours
with or without 0.4 μg/ml of cisplatin. In this case, cytotoxicity was
evaluated for the drug library alone, cisplatin treatment alone, and
each combination, and a greater than 20% difference in response
in the combination compared to either agent alone was considered
a “hit.”Statistical Analyses
Significance between MTT viability curves was determined by
one-way analysis of variance employing Bonferroni's multiple
comparison test, whereas evaluations between columns was per-
formed employing a two-way analysis of variance Bonferroni's
multiple-comparison test. The combination effect of vorinostat and
cisplatin was calculated using CalcuSyn computer software (Biosoft,
Cambridge, UK). Combination index (CI) values were graphed on
fraction affected-CI (Fa-CI) plots. A CI b 1 is a synergistic
interaction, CI = 1 is additive, and CI N 1 is antagonistic.
Results
Derivation of Cisplatin-Resistant NSCLC Sublines
In this study, we developed a series of cisplatin-resistant clones
from the Calu6 and H23 NSCLC cell lines (designated Calu6cisR1-3
and H23cisR1-3, respectively). Both parental cell lines are derived
from NSCLC adenocarcinomas and show genetic mutations in KRAS
and p53, common to this tumor type [22,23]. To derive Calu6 and
H23 sublines resistant to cisplatin, cells were plated and treated with
2 μg/ml of cisplatin until a surviving fraction of about 10−6 remained
[16]. Surviving colonies were then isolated and propagated for more
than 20 population doublings in the absence of cisplatin. Their
responsiveness to cisplatin, carboplatin, and the anthracycline
doxorubicin (an intercalating DNA-damaging agent [24], employed
as a comparator) was determined by the MTT Cell Viability Assay
following 48 hours of treatment (Figure 1A). The cisplatin and
carboplatin treatments followed a similar pattern, with all three
resistant cisR sublines demonstrating significantly less cytotoxicity.
The Calu6cisR sublines demonstrated more variability in their
responses, whereas the H23cisR sublines showed a more consistent
and reduced cytotoxic response to cisplatin and carboplatin. The
resistant phenotype was restricted to platins, as all of the resistant
clones with the exception of Calu6cisR3 showed similar cytotoxicity
to their parental counterparts in response to doxorubicin (Figure 1A).
To further characterize these cisplatin-resistant sublines, we
determined their proliferation rate measured by trypan blue exclusion
cell counts, with measurements carried out over 200 hours in culture.
The H23 parental and their cisR sublines (data not shown) showed
similar doubling time kinetics. However, the Calu6cisR sublines,
demonstrating similar cellular morphology to their parental counter-
parts (Figure 1B), displayed a significantly lower rate of proliferation
as assessed by their doubling time. The slow growth of Calu6cisR3
correlates with its enhanced resistance to the above agents. Following
the assessment of their growth kinetics, we focused our subsequent
experiments on comparing Calu6 versus Calu6cisR1 and H23 versus
H23cisR1.
Differential Induction of ATF3 in Cisplatin-Sensitive NSCLC
Cells
Differentially expressed genes between cells sensitive or resistant to
cisplatin following treatment may identify key regulators driving the
tumor cell–induced cytotoxicity of this important clinical agent. To
identify such differentially regulated genes, we compared
cisplatin-sensitive parental lines Calu6 and H23 to their representa-
tive matching resistant sublines Calu6cisR1 and H23cisR1 by
performing RNA-seq full transcriptome analysis. We compared
expression levels of each parental line to its paired cisR1 resistant
subline treated with cisplatin (2 μg/ml, 24 hours). We focused on
differentially expressed genes that were cisplatin dependent, limiting
Figure 1. (A) MTT analysis of Calu6, Calu6cisR1-3, H23, and H23cisR1-3 following 48-hour treatments with cisplatin, carboplatin, and
doxorubicin. Cisplatin and carboplatin treatments showed reduced cytotoxicity in the Calu6cisR1-3 and H23cisR1 compared to their
parental cell lines. With the exception of Calu6cisR3, response to doxorubicin treatment was similar in the parental and cisR1 sublines.
*Significant difference in the viability curves of the cisR sublines compared to their parental counterparts (Pb .05). (B) No significant
morphological differences were observed between the parental and resistant sublines (phase microscopy); however, proliferation rates
as determined by cell doubling times were reduced in the Calu6cisR sublines, and this was most pronounced in the Calu6cisR3 cell line.
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performed by StemCore (Ottawa Hospital Research Institute) using
an Illumina GAIIx platform [25,26] generating 40 million
sequencing reads per sample with 89% to 90% of reads mapping
back to the genome. In the Calu6 versus Calu6cisR1 cells, 932 genes
were differentially expressed, whereas in the H23 versus H23cisR1-
cells, 601 genes were differentially expressed (Log2N ±2). A total of 42
differentially induced genes were identified that were common to
both cell lines (Figure 2A).
Exploring the top differentially expressed genes (top five shown in
Supplemental Table 1), we found ATF3 to be the most significantly
upregulated gene in both parental cell lines compared to their cisR1
sublines (Figure 2B). We further expanded on these results to
determine the levels of ATF3 expression following the cytotoxic dose
of 4 μg/ml of cisplatin for up to 24 hours in the Calu6 cell line and all
three of its respective resistant sublines. Employing Q-RT-PCR, the
differential induction of ATF3 following cisplatin treatment is clearly
demonstrated, as only the Calu6 parental line showed significant
ATF3 expression. ATF3 mRNA was induced in a time-dependant
fashion, requiring at least 12 hours to become clearly evident
(Figure 2C). Western blot analyses of both the Calu6 and the H23Figure 2. (A) RNA-seq analysis of Calu6 and H23 parental versus
differentially expressed genes in both cell lines following 2-μg/ml cisp
ATF3 was differentially induced in cisplatin-treated sensitive parental
determined in this analysis (2-μg/ml cisplatin treatments for 24 hou
expression of ATF3 in cisplatin-treated Calu6 cells compared to the
4-μg/ml treatments of cisplatin for up to 24 hours. (D) Western blot ana
cell lines compared to their Calu6cisR1-3 and H23cisR1-3 cisplatin
cisplatin for 24 hours.and their derived cisR1-3 sublines demonstrated that significant
induction of ATF3 by cisplatin treatment (4 μg/ml, 24 hours) is
specific to the sensitive parental lines compared to their resistant cisR
sublines (Figure 2D).
Cisplatin Induces ATF3 Expression in Ex Vivo NSCLC
Tumors
To determine the ability of cisplatin to induce ATF3 expression
in patient-derived NSCLC tissue as a more relevant clinical model,
we evaluated ex vivo tissue samples from patients undergoing
surgery for NSCLC. Tumor tissue and adjacent normal controls
from six NSCLC patients were assayed for ATF3 expression
employing Q-RT-PCR following 48 hours of treatment. ATF3
induction of greater than five-fold (normal untreated tissue used to
normalize in all cases) was considered as a significant induction
that is in line with our cell-line data. In all of the six patient tissues
evaluated, the normal lung tissue failed to significantly induce
ATF3 (Figure 3). In the tumor tissues, three of six showed
significant ATF3 induction following cisplatin treatment. This is
the first report of the ability of cisplatin to induce ATF3 directly in
tumor tissue.their respective cisR1 resistant clones identified 42 commonly
latin treatment for 24 hours. (B) The cellular stress response gene
lines but not their cisR1 sublines as indicated by the RNA-seq reads
rs). (C) Q-RT-PCR confirmed and expanded upon the differential
ir Calu6cisR1-3 cisplatin-resistant sublines following the cytotoxic
lysis of ATF3 expression in cisplatin-treated Calu6 and H23 parental
-resistant sublines following the cytotoxic 4-μg/ml treatments of
Figure 3. Levels of ATF3 mRNA following solvent or cisplatin treatments (0, 4, and 8 μg/ml) for 48 hours in six NSCLC (T) and adjacent
normal (N) ex vivo tissues. Cisplatin-induced expression of greater than five-fold was observed in three of six NSCLC tissue samples
evaluated but in none (0/6) of the normal adjacent tissues evaluated.
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Because previous studies have demonstrated that MAPKinases
can regulate cisplatin-induced cytotoxicity [13] as well as ATF3
expression [15], we evaluated the status and activation of the JNK
(assayed by evaluating the phosphorylation of its target c-jun [27]),
ERK (assayed by phopho-ERK levels), and p38 (assayed by evaluating
the phosphorylation of its targetHSP27 [28]) following similar 4-μg/ml
cisplatin treatments in Calu6 and Calu6cisR1 and in H23 and
H23cisR1 (Figure 4A). In both cases, the parental cells showed
significant JNK activation in a time-dependant manner. JNK
activation was pronounced by 12 hours of treatment while lacking
in both resistant cisR1 sublines. Significant activation of the ERK and
p38 pathways was not readily detected either in the parental NSCLC
cell lines or in their resistant sublines following cisplatin treatments
(Figure 4A). To determine if the observed JNK activation mirrored
the induction pattern of ATF3 as well, we performed a dose- and
time-dependant assessment of ATF3 expression and p-c-jun
induction in both parental cell lines (Supplemental Figure 1).
Calu6 and H23 cells were treated with 0, 1, 2, and 4 μg/ml of
cisplatin for 12, 24, and 36 hours and evaluated for ATF3 expression
and phosphorylation levels of c-jun. In both cell lines, ATF3 was
induced in a time- and dose-dependent manner. This expression
pattern closely mirrored the phosphorylation levels of c-jun induced
by cisplatin treatments (Supplemental Figure 1).
To expand on these findings, we evaluated ATF3 and phosphor-
ylated c-jun levels following 24-hour cisplatin treatments (0-8 μg/ml)
in the breast cancer cell lines MCF7 and T47D and in the prostate
cancer–derived cell lines LNCAP and PC3 (Supplemental Figure 1).
Similarly, ATF3 was induced in a dose-dependent manner in all fourcell lines tested. These expression levels also closely mirrored
cisplatin-induced phosphorylation of c-jun and were in line with
previously published studies [14,15,19]. To determine the role of
JNK activity in both cisplatin resistance and lack of ATF3 induction,
we treated Calu6 with 10 μM of the JNK inhibitor SP600125 in
combination with 1 and 4 μg/ml of cisplatin for 48 hours. Cells
treated with the JNK inhibitor were less responsive to
cisplatin-induced cytotoxicity (Figure 4B). In the Calu6cisR1 subline,
expression of a hyperactive JNK construct [17] enhanced
cisplatin-induced cytotoxicity, as assessed by the MTT cell viability
assay (Figure 4C). Expression of the hyperactive JNK had no impact
on cytotoxicity in the absence of cisplatin exposure. Furthermore,
active JNK rescued cisplatin-induced ATF3 expression in the
Calu6cisR1 subline, as assessed by Western blot analysis (Figure 4D).
ATF3 Induction by DNA Damaging Agents
To determine the role that ATF3 plays in regulating the
cytotoxicity of a variety of chemotherapeutic agents, we evaluated
the cytotoxic effects of these agents in ATF3 null (−/−) cells and their
respective wild-type MEF counterparts. Evaluated agents included
cisplatin, carboplatin, doxorubicin, and docetaxel that targets tubulin
cytoskeleton and acts as a mitotic poison [29] (Figure 4A). MTT cell
viability assays demonstrated ATF3−/− MEFs to be resistant to
cisplatin, carboplatin, and doxorubicin, but there was no difference in
sensitivity to docetaxel (Figure 5A).
We further evaluated the sensitivity of the Calu6 and H23 cell lines
and their respective resistant subline (cisR1) to docetaxel treatment as
above and showed no differential sensitivity between the parental and
cisR1 sublines (Figure 5B). The other three agents' sensitivities were
Figure 4. (A) Following 4-μg/ml cisplatin treatments for up to 24 hours, Western blot analysis showed differential induction of JNK
MAPKinase activation (through phosphorylated c-jun) but not ERK (phospho-ERK) or p38 (through phosphorylated HSP27) in both Calu6
and H23 cells. This induction was abrogated in their respective cisR1 sublines. (B) MTT analysis of Calu6 cells following 48-hour
treatments of (0, 1, and 4 μg/ml) cisplatin with or without 10-μM treatment of the JNK inhibitor SP600125. *Significant differences
between columns highlighted (Pb .05). (C) Exogenous expression of a JNK-activated construct enhanced cisplatin cytotoxicity in the
Calu6cisR1 subline as assessed by MTT cell viability assay following 48-hour cisplatin treatments. *Pb .05 between columns highlighted.
(D) Exogenous expression of activated JNK in Calu6cisR1 also rescued cisplatin-inducible ATF3 expression in these cells assessed by
Western blot analysis (24-hour treatments).
Figure 5. (A) MTT analysis of wild-type and ATF3−/− MEFs following 48-hour treatments of cisplatin, carboplatin, doxorubicin, and
docetaxel. Loss of ATF3 inhibits cisplatin-, carboplatin-, and doxorubicin-induced cytotoxicity but had no effect on docetaxel cytotoxicity.
*Significant difference in the viability curves comparing the wild-type and the ATF3−/− MEFs responses (Pb .05). (B) MTT analysis of
Calu6, Calu6cisR1, H23, and H23cisR1 following 48-hour treatments with docetaxel showing no significant differences in sensitivity
(note: cisplatin, carboplatin, and doxorubicin treatments were presented in Figure 1A). (C) Western blot analysis shows significant ATF3
induction restricted to the parental cell lines with cisplatin and carboplatin treatments. Doxorubicin treatments showed similar ATF3
induction in both the parental and their cisR1 sublines. No significant ATF3 induction was observed with the docetaxel treatments in any
of the lines tested, with a weak induction in the H23 series (24-hour treatments, IC50 dose).
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following treatments (IC50 concentrations employed for 24 hours),
differential ATF3 expression following carboplatin treatments was
observed in a similar pattern to cisplatin (Figure 5C). Doxorubicin
was also a potent inducer of ATF3; however, unlike the platins, both
the parental and the resistant sublines readily induced ATF3.
Furthermore, ATF3 was not readily induced with weak induction
in the H23 and H23cisR1 in the docetaxel-treated cells even with
similar levels of cell cytotoxicity observed (Figure 5C).
Inducers of ATF3 Enhance Cisplatin Cytotoxicity
We aimed to examine whether inducers of ATF3 expression can
enhance the cytotoxicity of cisplatin. A high-throughput drug screen
to identify agents whose cytotoxicity was ATF3 dependent was
conducted. Both wild-type (ATF3+/+) and null ATF3−/−MEFs were
treated with a chemical library of 1200 FDA-approved compounds at
5 μM for 48 hours (Supplemental Table 2a). We identified 41 agents
that displayed a greater than 20% cytotoxicity in the ATF3+/+
compared to the ATF3−/− MEFs (less than a 2% “hit” rate),
indicating a level of specificity to this approach, including the
identification of three agents that we have shown to be ATF3
inducers in our previous work [30–32]. A secondary screen with
the Calu6 cell line used 1-μM library pretreatments for 24 hours
followed by 0.4-μg/ml cisplatin treatment or no treatment for an
additional 48 hours. In this screen, 12 agents were identified with
at least a 20% higher cytotoxicity in the combination treatment
than either the library and cisplatin treatments alone (Supplemental
Table 2b).
Of interest, vorinostat was identified in both library screens and
was previously shown to enhance cisplatin responsiveness [32,33];
however, the mechanism of action of this phenomenon has not been
determined. We first confirmed the differential sensitivity of the
wild-type and ATF3−/−MEFs to vorinostat treatments employing 0-
to 10-μM treatments for 48 hours (Figure 6A), clearly demonstrating
a role for ATF3 in regulating vorinostat cytotoxicity. Employing these
MEFs cell lines, we also demonstrated that the enhanced cytotoxicity
of 24-hour pretreatment with either 1 or 2 μM vorinostat with
cisplatin (further 48 hours) was dependant on ATF3 as significant
cytotoxicity was observed only in the wild-type but not the ATF3−/−
deficient MEFs (Figure 6B). In the NSCLC cells, similar to their
resistance to cisplatin, H23cisR1 showed a more robust resistance to
vorinostat than Calu6cisR1 when compared to their parental lines
(Figure 6C). Vorinostat is a potent inducer of ATF3 in both the
Calu6 and H23 cells with an attenuated but discernable response in
the cisR1 cells following 24 hours of treatment (Figure 6D). In both
the parental Calu6 and H23 cells and their cisR1 derivatives,
vorinostat enhanced the cytotoxicity of cisplatin (0-, 1-, 2-, or
5-μM 24-hour vorinostat pretreatment followed by 48 hours of
cisplatin in combination with vorinostat) as determined by MTT
analysis (Figure 6, E and F). This combination generally induced
synergistic cytotoxicity, particularly at the 2-μM vorinostat
concentration, as determined by CI evaluation, even within the
cisR1 sublines (Supplemental Figure 2). Furthermore, in the
Calu6cisR1 and H23cisR1sublines, 24-hour treatments with 5
μM vorinostat followed by 24-hour treatment with either 2 or 4
μg/ml of cisplatin showed enhanced ATF3 induction in the
combination treatments (Figure 6G). This suggests a potential role
for ATF3 expression in overcoming cisplatin resistance that
requires further study.Discussion
Lung cancer, predominantly NSCLC, is the most common cause of
death from cancer worldwide [1]. The platins cisplatin and
carboplatin are among the most active agents, with platin
combination chemotherapy typically the first-line therapy in
advanced disease. Nonetheless, benefit is limited, with few patients
remaining progression free at 5 years [2]. New combinations of
platins with novel agents are urgently required [4]. The mechanisms
regulating platin cytotoxicity are currently poorly understood [7,34],
and understanding these mechanisms could suggest 1) rational
strategies strategies to enhance their efficacy and 2) clinically useful
predictive biomarkers of platin response.
In this study, we established a number of cisplatin-induced
resistant clones (cisR) in the Calu6 and H23 NSCLC-derived cell
lines. Employing RNA-seq analyses, we identified ATF3 expression as
a highly significant cisplatin differentially induced gene in the
sensitive parental lines Calu6 and H23 compared to their
cisplatin-resistant counterparts. The ability of cisplatin to induce
ATF3 was also demonstrated in a cohort of NSCLC surgically excised
NSCLC tissue ex vivo but not in their adjacent normal lung tissue.
The MAPKinase pathways play a significant role in regulating both
cisplatin cytotoxicity and ATF3 expression [9,19,35]. Cisplatin-
induced MAPKinase activation, specifically activation of the JNK
pathway, was abrogated in Calu6cisR1 and H23cisR1 cells.
Furthermore, expression of activated JNK enhanced cisplatin
cytotoxicity and ATF3 expression in the Calu6cisR1 resistant subline.
Furthermore, MEFs deficient in ATF3 were resistant to cisplatin and
carboplatin but not to the tubulin stabilizer docetaxel compared to
their wild-type counterparts. The inability to induce ATF3 may
represent a novel mechanism of cisplatin resistance that requires
further study. The small molecule library screens performed in this
study provide initial evidence that ATF3 activating agents can be
identified that enhance cisplatin response in both the sensitive
parental Calu6 and H23 cell lines but importantly also in their
respective cisR1 sublines. The HDAC inhibitor vorinostat was
identified in this study as an agent that both enhanced cisplatin
cytotoxicity in Calu6 cells but whose cytotoxicity was also regulated
in part by ATF3 in a subsequent screen comparing the cytotoxicity of
the same FDA-approved 1200 drugs in wild-type compared to ATF3−/−
deficient cells. Of the 1200 agents evaluated, only 41 showed significant
differential cytotoxicity between wild-type and ATF3−/− deficientMEFs,
indicating that there is specificity in the requirement for ATF3-induced
cytotoxicity. However, HDAC inhibitors like vorinostat do not show
specificity and affect multiple signaling pathways [36,37], and although
these drugs demonstrate preclinical and clinical activity in combination
with platins in NSCLC, off-target toxicities limited their utilization [38].
These data provide the rationale that ATF3 is a therapeutic target and the
identification of novel and more specific enhancers of ATF3may provide
a novel strategy for development of next-generation platin-combination
therapies.
With 30% to 50% of patients presenting with high-level intrinsic
platin resistance [39], development of reliable predictive markers of
platin response in NSCLC is also urgently needed. The markers or
gene signatures that have previously been explored relied on the
assessment of gene expression in archival or pretreatment patient
tumor samples, where tumor heterogeneity and instability of
potential biomarkers limit their reliability [40]. This is in contrast
to the predictive markers employed for EGFR and ALK targeted
agents, where the presence of EGFR mutations and ALK
Figure 6. (A) MTT analysis of wild-type and ATF3−/− MEFs following 48-hour treatments with vorinostat showing that loss of ATF3
inhibits vorinostat-induced cytotoxicity in MEFs. (B), MTT analysis of wild-type (wt) and ATF3−/− deficient MEFs following 24-hour
pretreatments of 1 and 2 μM vorinostat followed by cisplatin treatment in combination for a further 48 hours. Enhanced cytotoxicity with
the combination was observed only in the wild-type MEFs. (C) MTT analysis comparing response of Calu6 to Calu6cisR1 and H23 to
H23cisR1 following 0-, 1-, 2-, and 5-μM vorinostat treatment for 72 hours. The H23cisR1 showed significant resistance to vorinostat.
*Significant differences between columns highlighted (Pb .05). (D) Western blot analysis shows ATF3 induced by vorinostat treatments
(0-10 μM, 48 hours) in the Calu6 and the H23 parental lines that was evident but attenuated in their cisR1 sublines. (E) MTT analysis of
Calu6 and Calu6cisR1 and (F) H23 and H23cisR1 following 24-hour pretreatments of 0, 1, 5, and 5 μM vorinostat followed by cisplatin
treatment in combination for a further 48 hours. Enhanced cytotoxicity with the combination was observed in all four lines compared to
either agent alone. (G) Western blot analysis shows ATF3 induced by 2- and 4-mg/ml cisplatin treatment (24 hours) was enhanced by
vorinostat treatment (5 μM, 24-hour pretreatment) in the Calu6cisR1 and the H23cisR1 resistant sublines.
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A similar absence/presence marker associated with platin response
would represent a similar ideal predictive biomarker. Low basal levels
of ATF3 in all the cell lines and sublines evaluated, as well as inuntreated normal and tumor tissue, was in contrast to the significant
induction of ATF3 seen specifically in sensitive parental cell lines and
in a cohort of resected NSCLC surgical samples. This expression
profile suggests its potential as a treatment-induced biomarker of
534 ATF3: Potential novel therapeutic target Bar et al. Neoplasia Vol. 18, No. 9, 2016platin responsiveness. The feasibility of this approach was demon-
strated in this study as cisplatin induction of ATF3 (as assessed by
Q-RT-PCR) was observed in three of six tumor tissues but not in the
six normal tissues evaluated. These data demonstrate the ability to
rapidly evaluate ATF3 expression in ex vivo tissue samples within a
clinically relevant time window (72 hours in our study). We plan
further assessment of ex vivo ATF3 induction in NSCLC patients
undergoing treatment with platin-based regimens to determine if it is
a useful predictive biomarker of clinical response to platins.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.07.004.
Acknowledgements
We thank the team at StemCore (Ottawa Hospital Research
Institute) including Pearl Campbell as well as Ivan Gorn, Jennifer
E. L. Hanson, and Stephanie Reid for expert technical assistance.
The support of the surgeons in the Division of Thoracic Surgery at
the Ottawa Hospital (Drs. Sebastien Gilbert, Donna Maziak,
Andrew Seely, Farid Shamji, and Sudhir Sundaresan) has been
instrumental in procuring human tumor tissues.
References
[1] Abratt RP and Hart GJ (2006). 10-year update on chemotherapy for non–small
cell lung cancer. Ann Oncol 17(Suppl 5), v33–v36.
[2] Kelland L (2007). The resurgence of platinum-based cancer chemotherapy. Nat
Rev Cancer 7, 573–584.
[3] Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM,
Gebbia V, Smit EF, Morabito A, and Gallo C, et al (2009). Meta-analysis of
single-agent chemotherapy compared with combination chemotherapy as
second-line treatment of advanced non–small-cell lung cancer. J Clin Oncol
Off J Am Soc Clin Oncol 27, 1836–1843.
[4] Souquet PJ, Chauvin F, Boissel JP, and Bernard JP (1995). Meta-analysis of
randomised trials of systemic chemotherapy versus supportive treatment in
non-resectable non–small cell lung cancer. Lung Cancer 12(Suppl 1),
S147–S154.
[5] Seve P and Dumontet C (2005). Chemoresistance in non–small cell lung cancer.
Curr Med Chem Anticancer Agents 5, 73–88.
[6] Stewart DJ (2007). Mechanisms of resistance to cisplatin and carboplatin. Crit
Rev Oncol Hematol 63, 12–31.
[7] Siddik ZH (2003). Cisplatin: mode of cytotoxic action and molecular basis of
resistance. Oncogene 22, 7265–7279.
[8] Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, and Perego P (2003).
Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA
mismatch repair. Curr Cancer Drug Targets 3, 21–29.
[9] Sedletska Y, Giraud-Panis MJ, and Malinge JM (2005). Cisplatin is a
DNA-damaging antitumour compound triggering multifactorial biochemical
responses in cancer cells: importance of apoptotic pathways. Curr Med Chem
Anticancer Agents 5, 251–265.
[10] Karin M and Gallagher E (2005). From JNK to pay dirt: jun kinases, their
biochemistry, physiology and clinical importance. IUBMB Life 57, 283–295.
[11] Sanchez-Prieto R, Rojas JM, Taya Y, and Gutkind JS (2000). A role for the p38
mitogen-activated protein kinase pathway in the transcriptional activation of p53
on genotoxic stress by chemotherapeutic agents. Cancer Res 60, 2464–2472.
[12] Bragado P, Armesilla A, Silva A, and Porras A (2007). Apoptosis by cisplatin
requires p53 mediated p38alpha MAPK activation through ROS generation.
Apoptosis 12, 1733–1742.
[13] Brozovic A and Osmak M (2007). Activation of mitogen-activated protein
kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 251, 1–16.
[14] Cai Y, Zhang C, Nawa T, Aso T, Tanaka M, Oshiro S, Ichijo H, and Kitajima S
(2000). Homocysteine-responsive ATF3 gene expression in human vascular
endothelial cells: activation of c-Jun NH(2)-terminal kinase and promoter
response element. Blood 96, 2140–2148.
[15] Lu D, Chen J, and Hai T (2007). The regulation of ATF3 gene expression by
mitogen-activated protein kinases. Biochem J 401, 559–567.
[16] Bar J, Gorn-Hondermann I, Moretto P, Perkins TJ, Niknejad N, Stewart DJ,
Goss GD, and Dimitroulakos J (2015). miR profiling identifies cyclin-dependentkinase 6 downregulation as a potential mechanism of acquired cisplatin resistance
in non–small-cell lung carcinoma. Clin Lung Cancer 16, e121–e129.
[17] Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, and Davis RJ
(1994). JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds
and phosphorylates the c-Jun activation domain. Cell 76, 1025–1037.
[18] Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H,
Salzberg SL, Rinn JL, and Pachter L (2012). Differential gene and transcript
expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat
Protoc 7, 562–578.
[19] St Germain C, Niknejad N, Ma L, Garbuio K, Hai T, and Dimitroulakos J
(2010). Cisplatin induces cytotoxicity through the mitogen-activated protein
kinase pathways and activating transcription factor 3. Neoplasia 12, 527–538.
[20] Kroupis C, Stathopoulou A, Zygalaki E, Ferekidou L, Talieri M, and Lianidou
ES (2005). Development and applications of a real-time quantitative RT-PCR
method (QRT-PCR) for BRCA1 mRNA. Clin Biochem 38, 50–57.
[21] Wermuth CG (2004). Multitargeted drugs: the end of the "one-target-one-di-
sease" philosophy? Drug Discov Today 9, 826–827.
[22] Frese S, Brunner T, Gugger M, Uduehi A, and Schmid RA (2002).
Enhancement of Apo2L/TRAIL (tumor necrosis factor–related
apoptosis-inducing ligand)-induced apoptosis in non–small cell lung cancer
cell lines by chemotherapeutic agents without correlation to the expression level
of cellular protease caspase-8 inhibitory protein. J Thorac Cardiovasc Surg 123,
168–174.
[23] Takahashi T, Carbone D, Takahashi T, Nau MM, Hida T, Linnoila I, Ueda R,
and Minna JD (1992). Wild-type but not mutant p53 suppresses the growth of
human lung cancer cells bearing multiple genetic lesions. Cancer Res 52,
2340–2343.
[24] Havelka AM, Berndtsson M, Olofsson MH, Shoshan MC, and Linder S (2007).
Mechanisms of action of DNA-damaging anticancer drugs in treatment of
carcinomas: is acute apoptosis an "off-target" effect? Mini-Rev Med Chem 7,
1035–1039.
[25] Tariq MA, Kim HJ, Jejelowo O, and Pourmand N (2011). Whole-transcriptome
RNAseq analysis from minute amount of total RNA. Nucleic Acids Res 39, e120.
[26] Wang Y, Mehta G, Mayani R, Lu J, Souaiaia T, Chen Y, Clark A, Yoon HJ, Wan
L, and Evgrafov OV, et al (2011). RseqFlow: workflows for RNA-Seq data
analysis. Bioinformatics 27, 2598–2600.
[27] Levresse V, Marek L, Blumberg D, and Heasley LE (2002). Regulation of
platinum-compound cytotoxicity by the c-Jun N-terminal kinase and c-Jun
signaling pathway in small-cell lung cancer cells. Mol Pharmacol 62, 689–697.
[28] Kostenko S, Johannessen M, and Moens U (2009). PKA-induced F-actin
rearrangement requires phosphorylation of Hsp27 by the MAPKAP kinase MK5.
Cell Signal 21, 712–718.
[29] Muggia F and Kudlowitz D (2014). Novel taxanes. Anticancer Drugs 25,
593–598.
[30] Dayekh K, Johnson-Obaseki S, Corsten M, Villeneuve PJ, Sekhon HS,
Weberpals JI, and Dimitroulakos J (2014). Monensin inhibits epidermal growth
factor receptor trafficking and activation: synergistic cytotoxicity in combination
with EGFR inhibitors. Mol Cancer Ther 13, 2559–2571.
[31] Niknejad N, Gorn-Hondermann I, Ma L, Zahr S, Johnson-Obeseki S, Corsten
M, and Dimitroulakos J (2014). Lovastatin-induced apoptosis is mediated by
activating transcription factor 3 and enhanced in combination with salubrinal.
Int J Cancer 134, 268–279.
[32] St Germain C,O'Brien A, andDimitroulakos J (2010). Activating transcription factor
3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase
inhibitor M344 and cisplatin in combination. Cancer Cell Int 10, 32,1-11.
[33] Liu J, Edagawa M, Goshima H, Inoue M, Yagita H, Liu Z, and Kitajima S
(2014). Role of ATF3 in synergistic cancer cell killing by a combination of
HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human
colon cancer cells. Biochem Biophys Res Commun 445, 320–326.
[34] Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, Namiki M,
Kohri K, Matsushita Y, and Fujioka T, et al (2005). Predicting response to
methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy
for bladder cancers through genome-wide gene expression profiling. Clin Cancer
Res 11, 2625–2636.
[35] Lu D, Wolfgang CD, and Hai T (2006). Activating transcription factor 3, a
stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem 281,
10473–10481.
[36] Marks PA, Richon VM, and Rifkind RA (2000). Histone deacetylase inhibitors:
inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92,
1210–1216.
Neoplasia Vol. 18, No. 9, 2016 ATF3: Potential novel therapeutic target Bar et al. 535[37] Ververis K,HiongA, Karagiannis TC, and Licciardi PV (2013).Histone deacetylase
inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7, 47–60.
[38] Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, and
Hershberger PA (2010). Vorinostat increases carboplatin and paclitaxel activity
in non–small-cell lung cancer cells. Int J Cancer 126, 743–755.
[39] Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson
DH, andEasternCooperativeOncologyG (2002). Comparison of four chemotherapy
regimens for advanced non–small-cell lung cancer. N Engl J Med 346, 92–98.[40] Souglakos J (2015). Customizing chemotherapy in non–small cell lung cancer:
the promise is still unmet. Transl Lung Cancer Res 4, 653–655.
[41] Aisner DL and Marshall CB (2012). Molecular pathology of non-small cell lung
cancer: a practical guide. Am J Clin Pathol 138, 332–346.
[42] Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye
FJ, Lindeman N, and Boggon TJ, et al (2004). EGFR mutations in lung
cancer: correlation with clinical response to gefitinib therapy. Science 304,
1497–1500.
